Global Refurbished Medical Devices Market Size, Share & Forecast, By Product Type, End User & Distribution Channel, 2026-2031

The market was worth USD 19,400 million in 2025. This estimate covers professionally refurbished durable medical equipment sold with functional testing, documented restoration and associated warranty or installation support, while excluding devices sold used-as-is and repair-only service revenue. Diagnostic imaging is the largest revenue pool because CT, MRI, ultrasound, X-ray and image-guided systems carry high transaction values and specialized installation requirements. The estimate sits between published 2025 anchors of USD 17,340 million and USD 21,300 million.

The market is projected to reach USD 34,707 million by 2031, expanding at a 10.18% CAGR from the 2025 base. Growth is supported by hospital capital constraints, private diagnostic capacity expansion, OEM trade-in programs and sustainability-linked procurement. Volume should rise faster in Asia Pacific and emerging markets, while average transaction value increases as certified imaging and connected equipment gain mix. The forecast assumes no broad international prohibition on refurbished-device imports and continued availability of serviceable software, parts and technical labor.

Profit pools will shift from anonymous used-equipment resale toward certified refurbishment, warranty attachment, software upgrades and lifecycle service. Certified channels are modeled to rise from 57% of market revenue in 2025 to 69% in 2031. OEM programs can monetize trade-ins twice, first by supporting new-equipment replacement and then through refurbished resale, while independent specialists can defend margins through multi-vendor capability and faster parts access. Imaging systems remain the largest profit pool, but remote-service-enabled monitoring platforms should deliver stronger recurring revenue characteristics.

Regulatory fragmentation is the most material constraint because countries define servicing, remanufacturing, import eligibility and manufacturer responsibility differently. The FDA's June 2024 guidance improves clarity in the United States, but global trade remains exposed to inconsistent documentation, age limits and registration requirements. Software licenses, cybersecurity support and proprietary parts create a second constraint for digitally connected equipment. These factors can turn low-cost inventory into stranded assets if refurbishers cannot legally import, validate, install or maintain the system in the destination market.

Asia Pacific offers the strongest growth opportunity, with a modeled 12.3% CAGR during 2026-2031 versus 8.7% in North America and 9.2% in Europe. The region combines large patient populations, uneven access to advanced imaging, expanding private diagnostic networks and stronger sensitivity to new-equipment capital cost. However, growth will not be uniform because import rules and biomedical service capacity vary by country. Successful suppliers need local regulatory partners, trained engineers, spare-parts logistics and financing structures that align payments with provider cash flow.

Capital-efficient diagnostic capacity expansion has the greatest strategic impact. Refurbished equipment can be priced 25% to 60% below comparable new systems, allowing hospitals and independent providers to add capacity without proportionate balance-sheet pressure. This is especially important where CT, MRI and PET density is low or waiting times are high. The economic benefit extends beyond purchase price because certified programs can include installation, applications training, warranty and service, reducing execution risk compared with unverified used equipment.